Open AccessTocilizumab for treating severe COVID‐19 pneumonia refractory to combined hydroxychloroquine, lopinavir plus ritonavir, and favipiravir: A case series
Author(s) -
Surabotsophon Manoon,
KlaiOn Yingyot,
Thanachartwet Vipa,
Khunapornphairote Sirote,
Chamnanchanunt Supat,
Racharak Theerapat,
Laisuan Wannada,
Sahassananda Duangjai,
Hapunna Samlee,
Jinapuk Somjit,
Leelasetakul Suthee,
Desakorn Varunee
Publication year - 2020
Publication title -
clinical case reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.21
H-Index - 9
ISSN - 2050-0904
DOI - 10.1002/ccr3.3407
Subject(s) - medicine , tocilizumab , lopinavir , hydroxychloroquine , ritonavir , lopinavir/ritonavir , pneumonia , favipiravir , refractory (planetary science) , respiratory distress , covid-19 , surgery , virology , rheumatoid arthritis , disease , human immunodeficiency virus (hiv) , viral load , physics , astrobiology , antiretroviral therapy , infectious disease (medical specialty)
Three patients diagnosed with severe COVID‐19 pneumonia received treatment with hydroxychloroquine combined with lopinavir, ritonavir, and favipiravir. Two patients diagnosed early, received tocilizumab when the pneumonia became severe and survived. The thrid patient was diagnosed late and received tocilizumab when the disease progressed to acute respiratory distress syndrome, and died.